Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?

Executive Summary

As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference. 
Advertisement

Related Content

Biosimilar Leaders Compliment Pfizer For Calling Out Fellow Innovators, But Should FDA Play A Role To Dispel Misinformation?
Biosimilar Sponsors: We Need To Do A Better Job Educating Physicians And Patients
Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior
Interchangeability Won’t Solve US Biosimilar Market’s Woes, FDA’s Gottlieb Says
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel